Abstract:Importance: Community-acquired pneumonia (CAP) results in approximately 1.4 million emergency department visits, 740 000 hospitalizations, and 41 000 deaths in the US annually. Observations: Community-acquired pneumonia can be diagnosed in a patient with 2 or more signs (eg, temperature >38 °C or ≤36 °C; leukocyte count <4000/μL or >10 000/μL) or symptoms (eg, new or increased cough or dyspnea) of pneumonia in conjunction with consistent radiographic findings (eg, air space density) without an alternative explanation. Up to 10% of patients with CAP are hospitalized; of those, up to 1 in 5 require intensive care. Older adults (≥65 years) and those with underlying lung disease, smoking, or immune suppression are at highest risk for CAP and complications of CAP, including sepsis, acute respiratory distress syndrome, and death. Only 38% of patients hospitalized with CAP have a pathogen identified. Of those patients, up to 40% have viruses identified as the likely cause of CAP, with Streptococcus pneumoniae identified in approximately 15% of patients with an identified etiology of the pneumonia. All patients with CAP should be tested for COVID-19 and influenza when these viruses are common in the community because their diagnosis may affect treatment (eg, antiviral therapy) and infection prevention strategies. If test results for influenza and COVID-19 are negative or when the pathogens are not likely etiologies, patients can be treated empirically to cover the most likely bacterial pathogens. When selecting empirical antibacterial therapy, clinicians should consider disease severity and evaluate the likelihood of a bacterial infection-or resistant infection-and risk of harm from overuse of antibacterial drugs. Hospitalized patients without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days. Systemic corticosteroid administration within 24 hours of development of severe CAP may reduce 28-day mortality. Conclusions: Community-acquired pneumonia is common and may result in sepsis, acute respiratory distress syndrome, or death. First-line therapy varies by disease severity and etiology. Hospitalized patients with suspected bacterial CAP and without risk factors for resistant bacteria can be treated with β-lactam/macrolide combination therapy, such as ceftriaxone combined with azithromycin, for a minimum of 3 days.

How to assess survival prognosis in patients hospitalized for community-acquired pneumonia in 2024?

A new prediction model for assessing the clinical outcomes of ICU patients with community-acquired pneumonia: a decision tree analysis.

Predictive value of community-acquired pneumonia severity scores on lung cancer patients with immune checkpoint inhibitor-associated pneumonitis: a retrospective analysis

Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of a prospective observational cohort

Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia

Multivariate Model to Predict Survival in Community-Acquired Pneumonia

Long-Term Outcomes in Severe Community-Acquired Pneumonia

Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis

Comparison of performances between risk scores for predicting mortality at 30 days in patients with community acquired pneumonia

Utility of pneumonia severity assessment tools for mortality prediction in healthcare-associated pneumonia: a systematic review and meta-analysis

Serum Procalcitonin, White Blood Cell and Hypersensitive C-reactive Protein Combined with Age Established a New Prediction Model in Predicting ICU Admission in Adult Community-Acquired Pneumonia (CAP) Patients.

Application and comparison of scoring indices to predict outcomes in patients with healthcare-associated pneumonia

Long‐term Prognosis of Adolescent and Middle‐aged Chinese Patients with Low‐medium Risk Community‐acquired Pneumonia: A Cohort Study

A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia

Performance of risk scores in predicting mortality at 3, 6, and 12 months in patients diagnosed with community-acquired pneumonia

Comparison of Pneumonia Severity Index and CURB-65 Score with Laboratory Parameters in Predicting In-Hospital Mortality for Community Acquired Pneumonia

Validation and meta-analysis of various severity scale system for predicting mortality and ICU admission in com-munity-acquired pneumonia patients

N-Myc and STAT Interactor is a Novel Biomarker of Severity in Community-Acquired Pneumonia: A Cohort Study

The Comparisons of Severity Scoring Systems for Community Acquired Pneumonia Patients with Chronic Obstructive Pulmonary Disease

Analysis of prognostic factors for hospitalized patients aged 95 years and over with community-acquired pneumonia

Community-Acquired Pneumonia: A Review